OrthoPediatrics Corp stock (US68735M1027): pediatric specialist reports Q1 2025 growth and raised ou
OrthoPediatrics Corp reported strong Q1 2025 revenue growth and increased its full-year sales outlook, driven by continued demand for its pediatric orthopedic implants and trauma systems. The company specializes exclusively in medical devices for children and adolescents, differentiating itself from larger orthopedic manufacturers. This niche focus makes it an appealing investment for those interested in specialized medtech and pediatric care, though investors should be aware of the inherent volatility in specialized markets.
Orthopediatrics Corp Raises Outlook Amid EBITDA Turnaround
Orthopediatrics Corp (KIDS) reported a positive Q1 earnings call, highlighting accelerating growth, improved margins, and a return to positive adjusted EBITDA. The company saw record patient reach, double-digit revenue growth both domestically and internationally, and raised its full-year 2026 revenue guidance. Despite ongoing net losses, management expressed confidence in their strategy, driven by new product launches, specialty bracing expansion, and EU MDR approvals.
OrthoPediatrics Corp stock (US68735M1027): pediatric orthopedics specialist updates investors after latest earnings
OrthoPediatrics Corp, a specialist in pediatric orthopedics, recently released its latest quarterly figures, updating investors on its strategy. The company focuses exclusively on orthopedic solutions for children and adolescents, developing implants and instruments tailored to young patients' anatomy and growth patterns. Its core business revolves around proprietary systems for trauma, deformity correction, and spinal indications, commercialized through specialist sales teams and distribution partners working with pediatric hospitals.
OrthoPediatrics (Nasdaq:KIDS) - Análisis de acciones
This article provides a detailed analysis of OrthoPediatrics (Nasdaq:KIDS), a medical device company specializing in orthopedic products for children. It covers the company's financial performance, future growth prospects, past results, financial health, and recent news, including various analyst ratings and product announcements. The analysis highlights that the stock is currently not profitable and has experienced significant insider selling, yet analysts see potential in its long-range revenue outlook and new product launches.
Number of shareholders of OrthoPediatrics Corp. – NASDAQ:KIDS
This article provides financial information for OrthoPediatrics Corp. (NASDAQ: KIDS), specifically focusing on the number of shareholders. It appears to be a financial data snippet from TradingView, including market data and copyright information.
OrthoPediatrics (NASDAQ: KIDS) counsel gifts 2,479 Common Stock shares
OrthoPediatrics Corp.'s General Counsel and Secretary, Daniel J. Gerritzen, gifted 2,479 shares of Common Stock without receiving payment. Following this transaction, Gerritzen directly holds 147,054 shares, which include 121,054 restricted stock awards. This filing is classified as a neutral event, solely representing a bona fide gift.
OrthoPediatrics stock (US68735M1027): Pediatric orthopedic device maker trades near resistance
OrthoPediatrics Corp (KIDS) is trading at $17.79 on Nasdaq, with analysts giving it a "Moderate Buy" rating and a price target of $24.44, suggesting a 37.6% upside. The company specializes in pediatric orthopedic medical devices and has a market capitalization of $456.7 million. This niche focus and strong analyst sentiment make it an interesting play for investors in the medical device sector, despite modest year-to-date performance.
Is the Selloff in OrthoPediatrics Corp. (KIDS) Creating a Buying Opportunity?
Minot Light Capital Partners, in its Q1 2026 investor letter, highlighted OrthoPediatrics Corp. (NASDAQ: KIDS) as a top-10 holding despite its recent stock decline. The firm views current market volatility as creating attractive opportunities in out-of-favor sectors and has been increasing its stake in OrthoPediatrics. While acknowledging the company's potential, Minot Light Capital also suggests that certain AI stocks might offer higher returns in a shorter timeframe.
Canaccord Genuity initiates coverage of OrthoPediatrics (KIDS) with buy recommendation
Canaccord Genuity has initiated coverage of OrthoPediatrics (KIDS) with a buy recommendation. This positive analyst outlook indicates a belief in the company's future stock performance.
OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
OrthoPediatrics Corp. announced preliminary unaudited net revenue for Q4 and full year 2023, along with its 2024 financial guidance. The company expects Q4 2023 revenue of $37.6 million (21% growth) and full-year 2023 revenue of $148.7 million (22% growth). For 2024, OrthoPediatrics projects revenue between $197 million and $200 million, including contributions from its recent acquisition of Boston O&P, which is expected to be accretive to adjusted EBITDA in 2024.
KIDS SEC Filings - Orthopedia 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to OrthoPediatrics (KIDS) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading documents. It details OrthoPediatrics' financial condition, operations, and governance, with AI-powered summaries to highlight key information from regulatory disclosures. Investors can track material events, financial statements, and corporate actions.
OrthoPediatrics (KIDS) Q1 Losses Challenge Bullish Margin Narratives Despite 11.1% Revenue Growth
OrthoPediatrics (KIDS) reported Q1 2026 revenue of US$59.4 million and a US$0.45 basic EPS loss, marking continued unprofitability despite 11.1% annual revenue growth. Trailing 12-month net losses reached US$39.7 million, challenging bullish narratives about margin improvement. The stock trades at a P/S discount compared to peers, which analysts attribute to persistent losses and recent insider selling rather than weaker top-line performance.
OrthoPediatrics (NASDAQ: KIDS) posts 13% Q1 revenue rise but remains unprofitable
OrthoPediatrics Corp. (NASDAQ: KIDS) reported a 13% increase in Q1 2026 net revenue, reaching $59.4 million, driven by strong performance in trauma and deformity, scoliosis, and specialty bracing across both U.S. and international markets. Despite this revenue growth and maintaining a strong gross margin of 73%, the company recorded a net loss of $10.7 million, similar to the prior year, illustrating continued unprofitability. OrthoPediatrics also increased its liquidity with a new $20 million delayed draw term loan facility and saw an increase in goodwill to $115.2 million due to recent clinic acquisitions.
OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
OrthoPediatrics Corp. has expanded its Specialty Bracing portfolio with the launch of the TRAXIO Complete - Weight System, a Halo Gravity Traction system designed for gradual spinal realignment in pediatric patients. This system aims to advance pediatric spine care in children's hospitals by providing controlled, weight-based axial traction. The introduction of TRAXIO strengthens OrthoPediatrics' scoliosis product offerings and enhances its position as a comprehensive partner for pediatric spine surgeons.
OrthoPediatrics (KIDS) sees 2026 growth to ~$265M revenue and positive EBITDA
OrthoPediatrics Corp. (KIDS) has provided its 2026 outlook, projecting revenue between $263.0-$267.0 million and Adjusted EBITDA of approximately $25.0 million, targeting free cash flow breakeven. The company reported 2025 revenue of $236.3 million and a net loss of $39.6 million, but showed an improvement in Adjusted EBITDA to $2.2 million in Q1 2026. This guidance signals a strategic shift towards profitability and self-funded growth, building on strong performance in trauma, deformity, and scoliosis product lines.
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. (Nasdaq: KIDS) announced strong financial results for the first quarter of 2026, with a 13% revenue increase to $59.4 million and significant improvements in adjusted EBITDA and free cash flow. The company raised its full-year 2026 revenue guidance to a range of $263.0 million to $267.0 million, reflecting continued growth and momentum in its pediatric orthopedic business. Key drivers include robust international performance, OPSB growth, and advancements in product innovation.
OrthoPediatrics: Q1 Earnings Snapshot
OrthoPediatrics Corp. (KIDS) reported a first-quarter loss of $10.7 million, or 45 cents per share, adjusted to 42 cents per share. The orthopedic device maker posted revenues of $59.4 million and anticipates full-year revenue between $263 million and $267 million.
[8-K] ORTHOPEDIATRICS CORP Reports Material Event
OrthoPediatrics Corp. reported strong Q1 2026 financial results, with revenue increasing by 13% to $59.4 million and adjusted EBITDA turning positive at $2.2 million. The company also raised its full-year 2026 revenue guidance to a range of $263.0 million to $267.0 million, projecting 11% to 13% growth, and reiterated expectations for approximately $25.0 million in adjusted EBITDA and breakeven free cash flow. This performance, driven by growth in Trauma & Deformity and Scoliosis products both domestically and internationally, signals operational momentum and improved profitability.
OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
OrthoPediatrics Corp. has expanded its Specialty Bracing portfolio with the launch of the TRAXIO Complete - Weight System, a Halo Gravity Traction system developed in collaboration with Synetik Group, Inc. This system is designed for controlled, weight-based axial traction for gradual spinal realignment in pediatric patients within hospital environments. The introduction of TRAXIO strengthens OrthoPediatrics' commitment to pediatric scoliosis care, offering a reliable traction system that enhances patient safety and extends their continuum of care from bracing to surgery.
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. reported strong financial results for the first quarter of 2026, with a 13% increase in total revenue to $59.4 million and a significant improvement in adjusted EBITDA to $2.2 million. The company also reduced its free cash flow usage by 40% year-over-year and increased its full-year 2026 revenue guidance to a range of $263.0 million to $267.0 million. These positive results were driven by robust international performance, growth in Trauma & Deformity and Scoliosis products, and strategic scaling of its OPSB division.
OrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. reported strong first-quarter 2026 financial results, with significant revenue growth of 13% year-over-year to $59.4 million and a positive adjusted EBITDA of $2.2 million. The company also increased its full-year 2026 revenue guidance to between $263.0 million and $267.0 million, reflecting confidence in continued growth driven by successful scaling, market share gains, and innovative product launches. These results demonstrate solid operational execution and improved profitability.
OrthoPediatrics (KIDS) to Release Earnings on Thursday
OrthoPediatrics (NASDAQ:KIDS) is scheduled to release its Q1 2026 earnings after market close on Thursday, April 30th. Analysts anticipate an EPS loss of ($0.4367) and revenue of approximately $58.34 million, with continued losses projected for the current and next fiscal years. Despite recent insider selling, 32.7% of the stock is insider-owned and 69.1% is held by institutional investors.
(KIDS) Risk Channels and Responsive Allocation
This article provides a detailed stock analysis for Orthopediatrics Corp. (NASDAQ: KIDS), highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It outlines institutional trading strategies, including long, momentum breakout, and short positions, based on AI models. The analysis also features multi-timeframe signal analysis, identifying support and resistance levels across different time horizons.
OrthoPediatrics (NASDAQ: KIDS) proxy details board elections and executive pay
OrthoPediatrics (NASDAQ: KIDS) announced the details for its 2026 annual meeting on June 4, which will include the election of four directors, advisory votes on executive compensation and auditor appointment, and a proposal to amend its 2024 Incentive Award Plan to increase authorized shares. The proxy statement details board structure, executive pay which saw 2025 bonuses at 78.2% of target, and significant stock ownership by Squadron Capital LLC and insiders. The company emphasizes a compensation strategy aligning executive incentives with long-term stockholder value through a mix of base salary, annual cash bonuses, and multi-year vesting restricted stock awards.
Form ARS ORTHOPEDIATRICS CORP For: Dec 31
OrthoPediatrics Corp. released its annual report (Form ARS) for the fiscal year ended December 31, 2025. The company reported a net loss of $39.6 million, an increase from $37.8 million in 2024, despite a 15% revenue growth to $236.3 million. The report details significant developments in its product pipeline, including new plating platforms and scoliosis systems, alongside ongoing investments in international expansion and strategic acquisitions.
Form DEFA14A ORTHOPEDIATRICS CORP
This article announces that OrthoPediatrics Corp. has filed a DEFA14A form with the U.S. Securities and Exchange Commission. This form serves as Definitive Additional Materials related to a proxy statement under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates that no fee was required for this submission.
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its first quarter 2026 financial results on April 30, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a live and archived webcast available on its investor relations page. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 85 products across trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its first quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results. Investors can access a live and archived webcast of the event on the company's website.
OrthoPediatrics Details Clinic Expansion, New Launches, and 2026 Free Cash Flow Goal at Needham Conference
OrthoPediatrics (NASDAQ: KIDS) detailed its expansion plans for Orthotics & Prosthetics Services and Bracing (OPSB) clinics, targeting approximately 80 U.S. territories and aiming for positive free cash flow by 2026. The company also highlighted a robust product pipeline, including over 20 U.S. 7D units, the Playbook workflow tool, the iotaMotion robotic system, and a multi-year scoliosis "super cycle" with new implant rollouts. Management emphasized a shift towards profitability, expecting a stable gross margin and reduced set deployment costs.
OrthoPediatrics posts Q1 numbers April 30, call at 4:30 p.m. ET
OrthoPediatrics (KIDS) announced it will report its first-quarter 2026 financial results on April 30, 2026, after market close. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss the results, with a webcast available on its Investors page for at least 90 days. Investors are advised to monitor revenue growth, margins, adjusted EBITDA, and cash generation relative to targets.
OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its first quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results. Investors can access a live and archived webcast of the event on the company's website.
Needham Maintains OrthoPediatrics (KIDS) Buy Recommendation
This article provides details on Needham's reiterated Buy recommendation for OrthoPediatrics (KIDS). The firm maintained its price target of $37.00 for the company's stock. This indicates a continued positive outlook from Needham on OrthoPediatrics' performance.
Needham Maintains OrthoPediatrics (KIDS) Buy Recommendation
Needham has reaffirmed its Buy rating for OrthoPediatrics (KIDS). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Lake Street Initiates Coverage of OrthoPediatrics (KIDS) with Buy Recommendation
Lake Street has initiated coverage of OrthoPediatrics (KIDS) with a "Buy" recommendation. The firm has set a price target of $55.00 for the company's stock. This new coverage suggests a positive outlook on OrthoPediatrics' future performance.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 16, 2026, at 11:30 AM ET. An audio webcast of the discussion will be available on the OrthoPediatrics’ investor relations website, with a replay also accessible after the event. OrthoPediatrics is an orthopaedic company dedicated to advancing pediatric orthopaedics with a comprehensive product offering across multiple categories.
OrthoPediatrics establishes new $20 million delayed draw term loan facility
OrthoPediatrics Corp. (NASDAQ:KIDS) has secured a new delayed draw term loan facility of up to $20 million through an amendment to its existing credit agreement. This facility, with an interest rate based on SOFR plus 6.50% per annum, allows the company to draw capital in increments until June 30, 2027, and matures on August 5, 2029. The announcement follows a recent mixed earnings report where the company exceeded revenue expectations despite a wider-than-expected loss, and analysts like Needham raised their price target.
OrthoPediatrics (NASDAQ: KIDS) secures $20M delayed draw term loan
OrthoPediatrics Corp. (NASDAQ: KIDS) has amended its existing term loan agreement to include a new delayed draw term loan facility of up to $20.0 million. This facility provides the company with flexible access to capital in minimum $10.0 million increments until June 30, 2027, with interest at the SOFR rate plus 6.50% (with a 3.25% floor) and a 1.00% payment-in-kind option. The agreement aims to support future investments or working capital needs while preserving near-term cash flow, without requiring immediate drawing on the funds.
OrthoPediatrics establishes new $20 million delayed draw term loan facility
OrthoPediatrics Corp. (NASDAQ:KIDS) has established a new $20 million delayed draw term loan facility through an amendment to its existing credit agreement. This facility allows the company to access capital in increments until June 30, 2027, with an interest rate based on SOFR plus 6.50% per annum. The move comes as the company maintains a strong current ratio and has shown revenue growth, despite a recent wider-than-expected loss per share in Q4 2025.
OrthoPediatrics Adds $20 Million Delayed-Draw Term Loan Facility Under Braidwell-Led Agreement
OrthoPediatrics (KIDS) has amended its Credit Agreement to include a $20 million delayed-draw term loan facility with Braidwell-managed funds, enhancing liquidity and capital deployment options. The facility offers flexible drawdowns until June 2027 and matures in August 2029, with interest at SOFR plus 6.50% and various fees. This move provides the company with financial flexibility while preserving near-term cash flow without immediate draw requirements.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & Chief Executive Officer, Dave Bailey, and Chief Operating Officer & Chief Financial Officer, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. The event is scheduled for Tuesday, April 14, 2026, at 9:30 am ET, with an audio webcast and replay available on the company's investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering over 85 products across trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics CEO and CFO join live Needham webcast on April 14
OrthoPediatrics (NASDAQ: KIDS) announced that its CEO, Dave Bailey, and COO/CFO, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 9:30 am ET. An audio webcast of the discussion will be available on the company’s investor relations website, with a replay accessible after the event. This participation follows a series of positive company developments, including record 2025 revenue and strong 2026 guidance.
OrthoPediatrics Corp Stock: Specialized Pediatric Orthopedics Leader Faces Sector Headwinds and Grow
OrthoPediatrics Corp (NASDAQ: KIDS) is highlighted as a leader in specialized pediatric orthopedic solutions, serving a niche market distinct from larger competitors. The company's business model involves direct sales of implants and devices for trauma, deformity, spine, and sports medicine in children, supported by ongoing R&D and strategic acquisitions. While benefiting from high barriers to entry and strong clinical evidence, investors should consider risks such as reimbursement changes, sales force dependence, and competitive pressures.
KIDS PE Ratio & Valuation, Is KIDS Overvalued
OrthoPediatrics Corp (KIDS) is currently considered undervalued, with a fair price estimated between $31.81 and $77.22 compared to its current price of $15.20, indicating it is undervalued by 52.22%. Despite being undervalued by this metric, its current P/S ratio of 1.30 is significantly above the industry average of 3.87 which is deemed unsustainable given its 16.97% revenue growth. The article also details KIDS's P/B ratio, FCF yield, Forward P/E, and Forward P/S ratios as of April 1, 2026.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 9:30 am ET. An audio webcast will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on advancing pediatric orthopedics with a comprehensive product offering.
KIDS SEC Filings - Orthopedia 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to OrthoPediatrics Corp. (KIDS) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading information. It details the company's financial condition, operations, and governance, with AI-powered summaries to help investors quickly understand key points. The site highlights recent filings such as insider trading activity and board changes, offering a centralized resource for regulatory disclosures.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 9:30 am ET. An audio webcast and replay of the discussion will be available on the company's investor relations website. The company, founded in 2006, specializes in pediatric orthopedics, offering over 85 products across trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of "Moderate Buy" by Brokerages
Eleven brokerages have given OrthoPediatrics Corp. (NASDAQ:KIDS) an average rating of "Moderate Buy," with an average 12-month price target of $24.67. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with a negative net margin, and analysts project a negative EPS for the current year. Insiders have sold 58,171 shares recently, though they still hold a substantial 32.7% of the company's stock, and institutions have significantly modified their holdings.
[144] ORTHOPEDIATRICS CORP SEC Filing
This article reports on an SEC Form 144 filing by OrthoPediatrics Corp. (KIDS), detailing the proposed sale of 19,535 shares of common stock with an aggregate market value of $337,065.00 through Stifel Nicolaus & Company Inc. The securities were acquired on March 15, 2026, as restricted stock units via an equity compensation plan. The filing states that no material adverse information is known by the seller that has not been publicly disclosed.
OrthoPediatrics (KIDS) COO/CFO granted shares, sells stock for taxes
OrthoPediatrics Corp. COO and CFO, Fred Hite, reported receiving a grant of 77,405 shares of common stock on March 15, 2026. He subsequently sold 12,993 shares at $17.25 each on March 16, 2026, to cover tax withholding obligations associated with restricted share vesting. Following these transactions, Hite directly owns 277,477 shares of OrthoPediatrics Common Stock, which includes 197,765 restricted stock awards.
OrthoPediatrics (KIDS) CEO share sale covers tax withholding on RSUs
OrthoPediatrics Corp. President and CEO David R. Bailey sold 19,535 shares of common stock at $17.25 per share. This sale was conducted to satisfy tax withholding obligations triggered by the vesting of restricted stock, not as a discretionary investment move. Following the transaction, Bailey retains 298,020 shares, including 187,891 restricted stock awards, maintaining a significant equity position in the company.
